<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02754518</url>
  </required_header>
  <id_info>
    <org_study_id>IRB15-1410</org_study_id>
    <nct_id>NCT02754518</nct_id>
  </id_info>
  <brief_title>Demonstration of Reverse Remodeling Effects of Entresto. Using Echocardiography Endocardial Surface Analysis</brief_title>
  <official_title>Demonstration of Reverse Remodeling Effects of Entresto (Valsartan/Sacubitril) Using Echocardiography Endocardial Surface Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study intends to measure the effects of valsartan/sacubitril compared to baseline&#xD;
      standard medical heart failure therapy on reverse remodeling using echocardiographic&#xD;
      endocardial surface analysis techniques to assess changes in ventricular volume, function,&#xD;
      and shape.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study intends to measure the effects of valsartan/sacubitril compared to baseline&#xD;
      standard medical heart failure therapy on reverse remodeling using echocardiographic&#xD;
      endocardial surface analysis techniques to assess changes in ventricular volume, function,&#xD;
      and shape. Furthermore, Metaiodobenzylguanidine (MIBG) scintigraphy and the heart to&#xD;
      mediastinum ratio will be used to assess Left Ventricle (LV) volume regression and risk&#xD;
      reduction. The investigators also intend to measure the effects of valsartan/sacubitril on&#xD;
      exercise capacity as assessed by the 6 minute walk test and peak Volume of Oxygen (V02) on&#xD;
      cardiopulmonary exercise testing. Additionally, the investigators will examine the impact of&#xD;
      valsartan/sacubitril on functional status and quality of life using the Kansas City&#xD;
      Cardiomyopathy Questionnaire (KCCQ) and Qualia Health (a novel iPhone application that&#xD;
      incorporates Fitbit technology to provide a &quot;real time&quot; daily 6 minute step count and&#xD;
      assesses quality of life using a series of short targeted questions. The investigators will&#xD;
      also measure Brain Natriuretic Peptide (BNP), N-terminal of the Prohormone Brain Natriuretic&#xD;
      Peptide (NT-proBNP), and Rho-kinase (a biomarker associated with heart failure) levels at&#xD;
      multiple time-points throughout the study period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Actual">April 2019</completion_date>
  <primary_completion_date type="Actual">April 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in LV Remodeling 2D End-Diastolic Diameter (cm)</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>LV Remodeling 2D End-Diastolic Diameter (cm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in LV Remodeling 2D End-Systolic Diameter (cm)</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>LV Remodeling 2D End-Systolic Diameter (cm)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in LV Remodeling Global Longitudinal Strain (%)</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>LV Remodeling Global Longitudinal Strain (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in LV Remodeling Left Atrial Volume (mL)</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>LV Remodeling Left Atrial Volume (mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in LV Remodeling 3D End-Diastolic Volume (mL)</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>LV Remodeling 3D End-Diastolic Volume (mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in LV Remodeling 3D End-Systolic Volume (mL)</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>LV Remodeling 3D End-Systolic Volume (mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in LV Remodeling LV Ejection Fraction (%)</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>LV Remodeling LV Ejection Fraction (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in LV Remodeling Conicity (%)</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>LV Remodeling Conicity (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in LV Remodeling Sphericity (%)</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>LV Remodeling Sphericity (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in RV Remodeling End-Diastolic Volume (mL)</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>RV Remodeling End-Diastolic Volume (mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in RV Remodeling End Systolic Volume (mL)</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>RV Remodeling End Systolic Volume (mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in RV Remodeling Ejection Fraction (%)</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>RV Remodeling Ejection Fraction (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in RV Remodeling Septal Curvature (%)</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>RV Remodeling Septal Curvature (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in RV Remodeling Free-Wall Curvature (%)</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>RV Remodeling Free-Wall Curvature (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in RV Remodeling Tricuspid Regurgitation</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>RV Remodeling Tricuspid Regurgitation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Rho-associated Protein Kinase (ROCK)</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>Rho-associated protein kinase (ROCK)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in (MIBG) Early hm Ratio</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>Cardiac 123Iodine-metaiodobenzylguanidine (MIBG) Early heart/mediastinum ratio (hm) ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in (MIBG) Late hm Ratio</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>Cardiac 123Iodine-metaiodobenzylguanidine (MIBG) Late heart/mediastinum ratio (hm) ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in NT-proBNP Levels</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>NT-proBNP levels (pg/ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Exercise Performance - 6 Minute Walk</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>Exercise Performance - 6 Minute Walk</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Exercise Performance - CPX - Peak VO2 (mL/kg/Min)</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>Exercise Performance - CPX - Peak VO2 (mL/kg/min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Exercise Performance - CPX - Peak RER</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>Exercise Performance - CPX - Peak RER (Respiratory Exchange Ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Exercise Performance - CPX - VE/VC02</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>Exercise Performance - CPX - VE/VC02</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Pressure - Systolic (mmHg)</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>Blood Pressure - Systolic (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Blood Pressure - Diastolic (mmHg)</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>Blood Pressure - Diastolic (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in KCCQ - Physical Limitation</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in KCCQ - Symptom Stability</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in KCCQ - Symptom Frequency</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in KCCQ - Symptom Burden</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in KCCQ - Total Symptom</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in KCCQ - Self Efficacy</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in KCCQ - Quality of Life Score</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in KCCQ - Social Limitation</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in KCCQ - Overall Summary</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in KCCQ - Clinical Summary</measure>
    <time_frame>Baseline,1 year</time_frame>
    <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Open label Entresto</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entresto</intervention_name>
    <arm_group_label>Open label Entresto</arm_group_label>
    <other_name>valsartan/sacubitril</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females aged ≥18 years&#xD;
&#xD;
          2. Congestive Heart Failure (CHF) New York Heart Association (NYHA) class II-IV with 25%≤&#xD;
             Left Ventricular Ejection Fraction (LVEF) ≤40% (ECHO within last 6 months)&#xD;
&#xD;
               -  NT-proBNP ≥ 600 pg/mL OR&#xD;
&#xD;
               -  NT-proBNP ≥ 400 pg/mL and a hospitalization for heart failure within the last 12&#xD;
                  months&#xD;
&#xD;
          3. Stable and optimized on an angiotensin-converting-enzyme inhibitor (ACEI) equivalent&#xD;
             to enalapril ≥ 10 twice a day (BID) for at least 4 weeks&#xD;
&#xD;
          4. Stable and optimized on a beta-blocker for at least 4 weeks&#xD;
&#xD;
          5. Optimized dosing of aldosterone antagonist at stable dose for at least 4 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of angioedema&#xD;
&#xD;
          2. estimated glomerular filtration rate (eGFR) &lt; 30 ml/min/1.73 m2 at screening&#xD;
&#xD;
          3. Serum potassium &gt; 5.2 mmol/L at screening&#xD;
&#xD;
          4. Symptomatic hypotension as defined by Investigator, systolic blood pressure (SBP) &lt;&#xD;
             100 mmHg at screening&#xD;
&#xD;
          5. Current acute decompensated heart failure&#xD;
&#xD;
          6. History of severe pulmonary disease&#xD;
&#xD;
          7. Active malignancy&#xD;
&#xD;
          8. Requirement for treatment with both angiotensin-converting-enzyme inhibitor (ACEI) and&#xD;
             angiotensin receptor blockers (ARB)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Kalantari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 22, 2016</study_first_submitted>
  <study_first_submitted_qc>April 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2016</study_first_posted>
  <results_first_submitted>April 9, 2019</results_first_submitted>
  <results_first_submitted_qc>January 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 29, 2021</results_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Sacubitril and valsartan sodium hydrate drug combination</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT02754518/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This is a prospective, single-arm longitudinal study, 40 patients were initiated on valsartan/sacubitril after a two week run in period of ACE or ARB alone.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Open Label Entresto</title>
          <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Open Label Entresto</title>
          <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association (NYHA) Class</title>
          <description>New York Heart Association (NYHA) Functional Classification.&#xD;
I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, shortness of breath (SOB).&#xD;
II: Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, SOB.&#xD;
III: Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or SOB.&#xD;
IV: Unable to do any physical activity without discomfort. Symptoms of heart failure at rest.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Class II</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Class III</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Heart Failure Etiology</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ischemic (ICM)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nonischemic (NICM)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LV Remodeling</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>LV Ejection Fraction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conicity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.75" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sphericity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.73" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LV Remodeling-Global Longitudinal Strain (%)</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="-12.9" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LV Remodeling</title>
          <population>Some patients have incomplete data.</population>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Left Atrial Volume</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90.9" lower_limit="67.7" upper_limit="111.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3D End-Diastolic Volume</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="243.5" lower_limit="190.1" upper_limit="302.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3D End-Systolic Volume</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159.7" lower_limit="118.9" upper_limit="207.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LV Remodeling</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>2D End-Diastolic Diameter</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.0" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2D End-Systolic Diameter</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>RV Remodeling</title>
          <units>cm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>End-Diastolic Volume</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143" lower_limit="121" upper_limit="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End Systolic Volume</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" lower_limit="51" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>RV Remodeling</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Ejection Fraction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Septal Curvature</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.86" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>RV Remodeling - Free-Wall Curvature</title>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.17" lower_limit="1.09" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>RV Remodeling - Tricuspid Regurgitation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Trace</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild-Moderate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate-Severe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Exercise Performance- 6 Minute Walk</title>
          <units>Meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="425" spread="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Exercise Performance - CPX -Peak RER</title>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.14" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Exercise Performance - CPX - Peak VO2</title>
          <units>mL/kg/min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.5" lower_limit="13.7" upper_limit="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Exercise Performance - CPX - VE/VC02</title>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" lower_limit="29" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Systolic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127" spread="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Rho-kinase (Rock)</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" lower_limit="0.7" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>hm ratio</title>
          <population>Some patients have incomplete data.</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>(MIBG) Early hm ratio</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.54" lower_limit="1.34" upper_limit="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>(MIBG) Late hm ratio</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.43" lower_limit="1.27" upper_limit="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NT-proBNP levels</title>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="333" lower_limit="130" upper_limit="1003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Kansas City Cardiomyopathy Questionnaire (KCCQ)</title>
          <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
          <population>Clinical Summary Score is the sum of total symptom and physical function, and then rescaled to range from 0-100. Overall Summary Score is sum of total symptom, physical function, social limitations, and quality of life scores, and then rescaled to range from 0-100.&#xD;
Some patients had incomplete data.</population>
          <units>scores on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <title>Physical limitation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90" lower_limit="71" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom Stability</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="50" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom Frequency</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89" lower_limit="74" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Symptom Burden</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92" lower_limit="79" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Symptom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89" lower_limit="71.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self Efficacy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88" lower_limit="75" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quality of Life Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" lower_limit="42" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Limitation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81" lower_limit="56" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall Summary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82" lower_limit="65" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clinical Summary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91" lower_limit="72" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in LV Remodeling 2D End-Diastolic Diameter (cm)</title>
        <description>LV Remodeling 2D End-Diastolic Diameter (cm)</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LV Remodeling 2D End-Diastolic Diameter (cm)</title>
          <description>LV Remodeling 2D End-Diastolic Diameter (cm)</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as means +/- standard deviations based upon the Shapiro-Wilks test of normality, and then analyzed with paired t-tests.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in LV Remodeling 2D End-Systolic Diameter (cm)</title>
        <description>LV Remodeling 2D End-Systolic Diameter (cm)</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LV Remodeling 2D End-Systolic Diameter (cm)</title>
          <description>LV Remodeling 2D End-Systolic Diameter (cm)</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as means +/- standard deviations based upon the Shapiro-Wilks test of normality, and then analyzed with paired t-tests.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in LV Remodeling Global Longitudinal Strain (%)</title>
        <description>LV Remodeling Global Longitudinal Strain (%)</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LV Remodeling Global Longitudinal Strain (%)</title>
          <description>LV Remodeling Global Longitudinal Strain (%)</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>percentage of global longitudinal strain</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.9" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.3" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as means +/- standard deviations based upon the Shapiro-Wilks test of normality, and then analyzed with paired t-tests.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in LV Remodeling Left Atrial Volume (mL)</title>
        <description>LV Remodeling Left Atrial Volume (mL)</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LV Remodeling Left Atrial Volume (mL)</title>
          <description>LV Remodeling Left Atrial Volume (mL)</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="67.7" upper_limit="111.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.6" lower_limit="49.8" upper_limit="90.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as medians (interquartile range) based upon the Shapiro-Wilks test of normality, and then analyzed with Wilcoxon signed-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in LV Remodeling 3D End-Diastolic Volume (mL)</title>
        <description>LV Remodeling 3D End-Diastolic Volume (mL)</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LV Remodeling 3D End-Diastolic Volume (mL)</title>
          <description>LV Remodeling 3D End-Diastolic Volume (mL)</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="243.5" lower_limit="190.1" upper_limit="302.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.2" lower_limit="118.8" upper_limit="214.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as medians (interquartile range) based upon the Shapiro-Wilks test of normality, and then analyzed with Wilcoxon signed-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in LV Remodeling 3D End-Systolic Volume (mL)</title>
        <description>LV Remodeling 3D End-Systolic Volume (mL)</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LV Remodeling 3D End-Systolic Volume (mL)</title>
          <description>LV Remodeling 3D End-Systolic Volume (mL)</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.7" lower_limit="118.9" upper_limit="207.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7" lower_limit="66.4" upper_limit="130.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as medians (interquartile range) based upon the Shapiro-Wilks test of normality, and then analyzed with Wilcoxon signed-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in LV Remodeling LV Ejection Fraction (%)</title>
        <description>LV Remodeling LV Ejection Fraction (%)</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LV Remodeling LV Ejection Fraction (%)</title>
          <description>LV Remodeling LV Ejection Fraction (%)</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>percentage of ejection fraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as means +/- standard deviations based upon the Shapiro-Wilks test of normality, and then analyzed with paired t-tests.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in LV Remodeling Conicity (%)</title>
        <description>LV Remodeling Conicity (%)</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LV Remodeling Conicity (%)</title>
          <description>LV Remodeling Conicity (%)</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>percentage of conicity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as means +/- standard deviations based upon the Shapiro-Wilks test of normality, and then analyzed with paired t-tests.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>t-test, 2 sided</method>
            <other_analysis_desc>paired t-test</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in LV Remodeling Sphericity (%)</title>
        <description>LV Remodeling Sphericity (%)</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LV Remodeling Sphericity (%)</title>
          <description>LV Remodeling Sphericity (%)</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>percentage of sphericity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as means +/- standard deviations based upon the Shapiro-Wilks test of normality, and then analyzed with paired t-tests.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.95</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in RV Remodeling End-Diastolic Volume (mL)</title>
        <description>RV Remodeling End-Diastolic Volume (mL)</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in RV Remodeling End-Diastolic Volume (mL)</title>
          <description>RV Remodeling End-Diastolic Volume (mL)</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143" lower_limit="121" upper_limit="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104" lower_limit="83" upper_limit="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as medians (interquartile range) based upon the Shapiro-Wilks test of normality, and then analyzed with Wilcoxon signed-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in RV Remodeling End Systolic Volume (mL)</title>
        <description>RV Remodeling End Systolic Volume (mL)</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in RV Remodeling End Systolic Volume (mL)</title>
          <description>RV Remodeling End Systolic Volume (mL)</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" lower_limit="51" upper_limit="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" lower_limit="35.4" upper_limit="72.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as medians (interquartile range) based upon the Shapiro-Wilks test of normality, and then analyzed with Wilcoxon signed-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in RV Remodeling Ejection Fraction (%)</title>
        <description>RV Remodeling Ejection Fraction (%)</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in RV Remodeling Ejection Fraction (%)</title>
          <description>RV Remodeling Ejection Fraction (%)</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>percentage of ejection fraction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as means +/- standard deviations based upon the Shapiro-Wilks test of normality, and then analyzed with paired t-tests.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Paired T-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in RV Remodeling Septal Curvature (%)</title>
        <description>RV Remodeling Septal Curvature (%)</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in RV Remodeling Septal Curvature (%)</title>
          <description>RV Remodeling Septal Curvature (%)</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>percentage of septal curvature</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as means +/- standard deviations based upon the Shapiro-Wilks test of normality, and then analyzed with paired t-tests.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in RV Remodeling Free-Wall Curvature (%)</title>
        <description>RV Remodeling Free-Wall Curvature (%)</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in RV Remodeling Free-Wall Curvature (%)</title>
          <description>RV Remodeling Free-Wall Curvature (%)</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>percentage of free-wall curvature</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" lower_limit="1.09" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" lower_limit="1.10" upper_limit="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as medians (interquartile range) based upon the Shapiro-Wilks test of normality, and then analyzed with Wilcoxon signed-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in RV Remodeling Tricuspid Regurgitation</title>
        <description>RV Remodeling Tricuspid Regurgitation</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in RV Remodeling Tricuspid Regurgitation</title>
          <description>RV Remodeling Tricuspid Regurgitation</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild-Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate-Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Trace</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mild-Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate-Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Severe</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as frequency and percentages based upon the Shapiro-Wilks test of normality, and then analyzed with the Fisher exact test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.07</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Rho-associated Protein Kinase (ROCK)</title>
        <description>Rho-associated protein kinase (ROCK)</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Rho-associated Protein Kinase (ROCK)</title>
          <description>Rho-associated protein kinase (ROCK)</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.7" upper_limit="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" lower_limit="0.5" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as medians (interquartile range) based upon the Shapiro-Wilks test of normality, and then analyzed with Wilcoxon signed-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in (MIBG) Early hm Ratio</title>
        <description>Cardiac 123Iodine-metaiodobenzylguanidine (MIBG) Early heart/mediastinum ratio (hm) ratio</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.&#xD;
0 participants analyzed at 1 year as data were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in (MIBG) Early hm Ratio</title>
          <description>Cardiac 123Iodine-metaiodobenzylguanidine (MIBG) Early heart/mediastinum ratio (hm) ratio</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.&#xD;
0 participants analyzed at 1 year as data were not collected.</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" lower_limit="1.34" upper_limit="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in (MIBG) Late hm Ratio</title>
        <description>Cardiac 123Iodine-metaiodobenzylguanidine (MIBG) Late heart/mediastinum ratio (hm) ratio</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.&#xD;
0 participants analyzed at 1 year as data were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in (MIBG) Late hm Ratio</title>
          <description>Cardiac 123Iodine-metaiodobenzylguanidine (MIBG) Late heart/mediastinum ratio (hm) ratio</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.&#xD;
0 participants analyzed at 1 year as data were not collected</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" lower_limit="1.27" upper_limit="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in NT-proBNP Levels</title>
        <description>NT-proBNP levels (pg/ml)</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in NT-proBNP Levels</title>
          <description>NT-proBNP levels (pg/ml)</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="333" lower_limit="130" upper_limit="1003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290" lower_limit="64" upper_limit="616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as medians (interquartile range) based upon the Shapiro-Wilks test of normality, and then analyzed with Wilcoxon signed-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Exercise Performance - 6 Minute Walk</title>
        <description>Exercise Performance - 6 Minute Walk</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Exercise Performance - 6 Minute Walk</title>
          <description>Exercise Performance - 6 Minute Walk</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="425" spread="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="486" spread="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as means +/- standard deviations based upon the Shapiro-Wilks test of normality, and then analyzed with paired t-tests.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Exercise Performance - CPX - Peak VO2 (mL/kg/Min)</title>
        <description>Exercise Performance - CPX - Peak VO2 (mL/kg/min)</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Exercise Performance - CPX - Peak VO2 (mL/kg/Min)</title>
          <description>Exercise Performance - CPX - Peak VO2 (mL/kg/min)</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>mL/kg/min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" lower_limit="13.7" upper_limit="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" lower_limit="14.8" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as medians (interquartile range) based upon the Shapiro-Wilks test of normality, and then analyzed with Wilcoxon signed-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Exercise Performance - CPX - Peak RER</title>
        <description>Exercise Performance - CPX - Peak RER (Respiratory Exchange Ratio)</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Exercise Performance - CPX - Peak RER</title>
          <description>Exercise Performance - CPX - Peak RER (Respiratory Exchange Ratio)</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as means +/- standard deviations based upon the Shapiro-Wilks test of normality, and then analyzed with paired t-tests.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-Values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>Paired t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Exercise Performance - CPX - VE/VC02</title>
        <description>Exercise Performance - CPX - VE/VC02</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Exercise Performance - CPX - VE/VC02</title>
          <description>Exercise Performance - CPX - VE/VC02</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="29" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" lower_limit="30" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as medians (interquartile range) based upon the Shapiro-Wilks test of normality, and then analyzed with Wilcoxon signed-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.82</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Pressure - Systolic (mmHg)</title>
        <description>Blood Pressure - Systolic (mmHg)</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure - Systolic (mmHg)</title>
          <description>Blood Pressure - Systolic (mmHg)</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131" lower_limit="122" upper_limit="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" lower_limit="105" upper_limit="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as medians (interquartile range) based upon the Shapiro-Wilks test of normality, and then analyzed with Wilcoxon signed-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Blood Pressure - Diastolic (mmHg)</title>
        <description>Blood Pressure - Diastolic (mmHg)</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Blood Pressure - Diastolic (mmHg)</title>
          <description>Blood Pressure - Diastolic (mmHg)</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="74" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="66" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as medians (interquartile range) based upon the Shapiro-Wilks test of normality, and then analyzed with Wilcoxon signed-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in KCCQ - Physical Limitation</title>
        <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in KCCQ - Physical Limitation</title>
          <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="71" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="88" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as medians (interquartile range) based upon the Shapiro-Wilks test of normality, and then analyzed with Wilcoxon signed-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in KCCQ - Symptom Stability</title>
        <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in KCCQ - Symptom Stability</title>
          <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="50" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="50" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as medians (interquartile range) based upon the Shapiro-Wilks test of normality, and then analyzed with Wilcoxon signed-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.17</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in KCCQ - Symptom Frequency</title>
        <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in KCCQ - Symptom Frequency</title>
          <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="74" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="85" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as medians (interquartile range) based upon the Shapiro-Wilks test of normality, and then analyzed with Wilcoxon signed-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.035</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in KCCQ - Symptom Burden</title>
        <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in KCCQ - Symptom Burden</title>
          <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="79" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="83" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as medians (interquartile range) based upon the Shapiro-Wilks test of normality, and then analyzed with Wilcoxon signed-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.059</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in KCCQ - Total Symptom</title>
        <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in KCCQ - Total Symptom</title>
          <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89" lower_limit="71.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="86" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as medians (interquartile range) based upon the Shapiro-Wilks test of normality, and then analyzed with Wilcoxon signed-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.054</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in KCCQ - Self Efficacy</title>
        <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in KCCQ - Self Efficacy</title>
          <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88" lower_limit="75" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="75" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as medians (interquartile range) based upon the Shapiro-Wilks test of normality, and then analyzed with Wilcoxon signed-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in KCCQ - Quality of Life Score</title>
        <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in KCCQ - Quality of Life Score</title>
          <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="42" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="67" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as medians (interquartile range) based upon the Shapiro-Wilks test of normality, and then analyzed with Wilcoxon signed-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P-Values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in KCCQ - Social Limitation</title>
        <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in KCCQ - Social Limitation</title>
          <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="56" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="81" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as medians (interquartile range) based upon the Shapiro-Wilks test of normality, and then analyzed with Wilcoxon signed-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>P-Values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in KCCQ - Overall Summary</title>
        <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in KCCQ - Overall Summary</title>
          <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" lower_limit="65" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="79.5" upper_limit="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as medians (interquartile range) based upon the Shapiro-Wilks test of normality, and then analyzed with Wilcoxon signed-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in KCCQ - Clinical Summary</title>
        <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
        <time_frame>Baseline,1 year</time_frame>
        <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Entresto</title>
            <description>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure. In this study subjects will take this drug as they normally would for their standard of care.&#xD;
Entresto</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in KCCQ - Clinical Summary</title>
          <description>KCCQ is a 23-item instrument that is self-administered. KCCQ measures physical function, symptoms (specifically frequency, severity, and recent change), social function, self-efficacy and knowledge, and quality of life. Subscales and Total Score range from 0-100; higher scores show better health status.&#xD;
Developed and validated by Dr. John Spertus,MD of University of Missouri-Kansas City.</description>
          <population>All subjects will take Entresto, a drug recently approved by the US Food and Drug Administration (FDA) for heart failure.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="72" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5" lower_limit="87" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Primary outcome was presented at baseline and 1-year as medians (interquartile range) based upon the Shapiro-Wilks test of normality, and then analyzed with Wilcoxon signed-rank test.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.056</p_value>
            <p_value_desc>P-values are not adjusted for multiple comparisons. Tests were two-tailed, considered statistically significant with a p-value &lt;0.05, and conducted using STATA MP version 15 (College Station, TX).</p_value_desc>
            <method>Sign test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Open Label Entresto</title>
          <description>REMODEL is a prospective, single-arm longitudinal study investigating the structural, neurohormonal and functional effects of sacubitril/valsartan. Patients with New York Heart Association (NYHA) Class II-III HFrEF who were on optimal guideline directed medical therapy for at least three months with an LVEF between 20-40% who otherwise met inclusion and exclusion criteria similar to that of the Paradigm Trial were eligible for enrollment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Hypotension</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="40" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sara Kalantari, MD</name_or_title>
      <organization>University of Chicago</organization>
      <phone>773-834-6853</phone>
      <email>skalantari@medicine.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

